Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Descending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
65162-0844-50 65162-0844 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 10, 2017 Feb. 1, 2024 In Use
00009-1111-01 00009-1111 Irinotecan Hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 14, 1996 Oct. 31, 2017 In Use
00009-1111-02 00009-1111 Irinotecan Hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 14, 1996 In Use
00009-7529-03 00009-7529 Irinotecan Hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 14, 1996 In Use
00009-7529-04 00009-7529 Irinotecan Hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 14, 1996 In Use
00009-7529-05 00009-7529 Irinotecan Hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 14, 1996 In Use
58468-0357-01 58468-0357 Alemtuzumab Campath 30.0 mg/mL Immunotherapy Monoclonal Antibody CD52 Intravenous Nov. 30, 2009 In Use
58468-0357-03 58468-0357 Alemtuzumab Campath 30.0 mg/mL Immunotherapy Monoclonal Antibody CD52 Intravenous Nov. 30, 2009 In Use
00310-0512-28 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral April 1, 2018 July 31, 2021 In Use
00310-0512-60 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Oct. 31, 2017 In Use
00310-0512-95 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral April 1, 2020 In Use
50742-0519-02 50742-0519 cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 30, 2020 In Use
50742-0520-05 50742-0520 cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 30, 2020 In Use
43975-0307-10 43975-0307 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral March 20, 2018 In Use
43975-0308-10 43975-0308 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral March 20, 2018 In Use
54879-0021-01 54879-0021 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral May 8, 2018 In Use
54879-0022-01 54879-0022 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral May 8, 2018 In Use
62559-0931-01 62559-0931 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral June 22, 2020 Aug. 31, 2023 In Use
68001-0563-84 68001-0563 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 30, 2022 In Use
68001-0564-22 68001-0564 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 30, 2022 In Use
68001-0565-28 68001-0565 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 30, 2022 In Use
50742-0521-10 50742-0521 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Sept. 16, 2021 In Use
51407-0748-02 51407-0748 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous March 20, 2023 In Use
51407-0749-05 51407-0749 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous March 20, 2023 In Use
51407-0750-10 51407-0750 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous March 20, 2023 In Use
62559-0930-01 62559-0930 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral June 22, 2020 March 31, 2023 No Longer Used
70518-3275-00 70518-3275 Hydrocortisone CORTEF 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 28, 2021 In Use
73116-0115-01 73116-0115 duvelisib COPIKTRA 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0115-02 73116-0115 duvelisib COPIKTRA 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0125-01 73116-0125 duvelisib COPIKTRA 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0125-02 73116-0125 duvelisib COPIKTRA 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0215-28 73116-0215 Duvelisib COPIKTRA 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0215-56 73116-0215 Duvelisib COPIKTRA 15.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0225-28 73116-0225 Duvelisib COPIKTRA 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
73116-0225-56 73116-0225 Duvelisib COPIKTRA 25.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral Sept. 25, 2018 In Use
42388-0014-25 42388-0014 Cabozantinib COMETRIQ 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 29, 2012 May 31, 2016 No Longer Used
42388-0011-14 42388-0011 Cabozantinib COMETRIQ Chemotherapy Tyrosine Kinase Inhibitor VEGFR Nov. 29, 2012 In Use
42388-0012-14 42388-0012 Cabozantinib COMETRIQ Chemotherapy Tyrosine Kinase Inhibitor VEGFR Nov. 29, 2012 In Use
42388-0013-14 42388-0013 Cabozantinib COMETRIQ 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 29, 2012 In Use
55150-0326-01 55150-0326 CLOFARABINE CLOFARABINE 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Oct. 3, 2022 In Use
47426-0201-01 47426-0201 aprepitant CINVANTI 130.0 mg/18mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 3, 2018 In Use
62559-0680-30 62559-0680 Bicalutamide CASODEX 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral June 26, 2018 In Use
57894-0111-01 57894-0111 ciltacabtagene autoleucel CARVYKTI 100000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Feb. 28, 2022 In Use
57894-0111-02 57894-0111 ciltacabtagene autoleucel CARVYKTI 100000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Feb. 28, 2022 In Use
23155-0649-41 23155-0649 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Oct. 1, 2019 In Use
23155-0790-41 23155-0790 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea March 1, 2021 In Use
00781-3474-32 00781-3474 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea May 26, 2021 In Use
16729-0548-63 16729-0548 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Aug. 18, 2022 In Use
16729-0545-63 16729-0545 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Aug. 18, 2022 In Use
50742-0492-01 50742-0492 Carmustine CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea June 25, 2022 In Use

Found 10,000 results in 9 milliseconds — Export these results